News headlines about Perrigo (NYSE:PRGO) have trended somewhat positive on Friday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Perrigo earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 89 out of 100, indicating that recent media coverage is very likely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Perrigo Company (PRGO) Rating Reiterated by Jefferies Group LLC (americanbankingnews.com)
- Royal Bank Of Canada Increases Perrigo Company (NYSE:PRGO) Price Target to $64.00 (americanbankingnews.com)
- Perrigo Company (PRGO) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Perrigo Company (NYSE:PRGO) Announces Earnings Results, Beats Estimates By $0.28 EPS (americanbankingnews.com)
- Wall Street’s M&A Chatter From August 10: Perrigo, PayPal-Swift Financial, Invitation Homes-Starwood Waypoint (feeds.benzinga.com)
Several brokerages recently weighed in on PRGO. Goldman Sachs Group, Inc. (The) raised shares of Perrigo from a “sell” rating to a “neutral” rating and raised their price target for the company from $66.00 to $79.00 in a research report on Friday. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $66.00 target price on shares of Perrigo in a research report on Wednesday, May 24th. Deutsche Bank AG reissued a “buy” rating and set a $88.00 price objective (up previously from $86.00) on shares of Perrigo in a research report on Monday, July 17th. Canaccord Genuity set a $86.00 target price on shares of Perrigo and gave the company a “buy” rating in a research note on Monday, May 22nd. Finally, Cantor Fitzgerald assumed coverage on shares of Perrigo in a research note on Friday, June 16th. They set an “overweight” rating and a $85.00 target price on the stock. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $85.93.
Perrigo (PRGO) traded up 2.15% on Friday, hitting $78.49. 3,098,187 shares of the company’s stock were exchanged. Perrigo has a 12-month low of $63.68 and a 12-month high of $99.14. The company’s market cap is $11.26 billion. The company’s 50-day moving average price is $73.59 and its 200-day moving average price is $73.05.
Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Thursday, August 10th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.28. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.18 billion. Perrigo had a negative net margin of 43.81% and a positive return on equity of 11.79%. The company’s revenue was down 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.93 EPS. Analysts forecast that Perrigo will post $4.32 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Friday, August 25th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, August 23rd. This represents a $0.64 annualized dividend and a yield of 0.82%. Perrigo’s dividend payout ratio is currently -3.90%.
WARNING: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/08/11/perrigo-prgo-earns-daily-coverage-optimism-rating-of-0-12-updated-updated-updated.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
What are top analysts saying about Perrigo Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Perrigo Company and related companies.